24 May 2021 - Osimertinib (Tagrisso) has transformed the treatment paradigm for epidermal growth factor receptor mutation positive non-small cell lung cancer in the FLAURA and ADAURA studies, not only in the advanced but early stages of the disease. 

Comparison of its efficacy with that of first-generation drugs is meaningless. While osimertinib is reimbursable as the standard primary therapy in advanced non-small cell lung cancer in the U.S. and European countries, it failed to get insurance benefits in Korea.

Read Korea Biomedical Review article